Atezolizumab + Radium-223 Dichloride
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate-Resistant Prostate Cancer
Conditions
Castrate-Resistant Prostate Cancer
Trial Timeline
Sep 23, 2016 → Jul 31, 2019
NCT ID
NCT02814669About Atezolizumab + Radium-223 Dichloride
Atezolizumab + Radium-223 Dichloride is a phase 1 stage product being developed by Roche for Castrate-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02814669. Target conditions include Castrate-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02814669 | Phase 1 | Completed |
Competing Products
9 competing products in Castrate-Resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 | eFFECTOR Therapeutics | Phase 2 | 44 |
| AZD4635 + Durvalumab + Cabazitaxel | AstraZeneca | Phase 2 | 52 |
| Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 + Intermittent dosing of AZD5363 | AstraZeneca | Phase 1 | 33 |
| Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186 | AstraZeneca | Phase 1 | 33 |
| BEZ235 + Prednisone + Abiraterone acetate | Novartis | Phase 1/2 | 41 |
| Denosumab | Amgen | Phase 3 | 76 |
| Alobresib + Enzalutamide | Gilead Sciences | Phase 1/2 | 40 |
| ISIS EIF4E Rx + ISIS EIF4E Rx + ISIS EIF4E Rx + Prednisone + Docetaxel | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisone | Achieve Life Sciences | Phase 3 | 69 |